Lidocaine/epinephrine transdermal - Vyteris

Drug Profile

Lidocaine/epinephrine transdermal - Vyteris

Alternative Names: LidoSite

Latest Information Update: 06 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vyteris
  • Class Acetanilides; Analgesics; Catecholamines; Local anaesthetics; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 29 May 2013 Vyteris plans to sell transdermal drug delivery patents, subject to approval of US Bankruptcy Court
  • 14 Aug 2007 Vyteris launches lidocaine/epinephrine transdermal in the US physician's office market
  • 12 Jun 2007 Lidocaine/epinephrine transdermal marketing rights licensed to Laboratory Corporation of America Holdings (LabCorp) in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top